Epidemiological Study of Childhood Cancer in Cascavel Cancer Hospital Uopeccan among 2000 and 2014

• Autor(a) principal: Longo, Bruna Cristina
• Data de Publicação: 2021
• Outros Autores: Popiolek, Isabela Mangue, Vale, Natália Gomes do, Rangel, Ana Lúcia Carrinho Ayroza, Souza, Maria Daniela Basso de
• Tipo de documento: Artigo
• Idioma: por; eng
• Título da fonte: Revista Brasileira de Cancerologia (Online)
• Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/1224
• topic: Neoplasias; Criança; Adolescente; Estudos Epidemiológicos; Análise de Sobrevida; Neoplasms; Child; Adolescent; Epidemiologic Studies; Survival Analysis; Neoplasias; Niño; Adolescente; Estudios Epidemiológicos; Análisis de Supervivencia

Introduction: Hospital-based epidemiological studies on childhood cancer are important to show the profile of patients cared by the service. Objective: To evaluate the characteristics of cancer patients aged 0-19 years at the Cascavel Cancer Hospital Uopeccan (2000-2014). Method: Cross-sectional study that evaluated medical charts for the following outcomes: gender, age, color/race, comorbidities, family history of cancer, household, cancer type, staging, treatment, metastasis, recurrences, patient’s status at the end of study. Descriptive statistics, chi-square and Kaplan-Meier were applied. Results: Boys were more prevalent (55.2%), age range from 1 to 4 years (36.3%), White (87%), urban household (81.6%), with leukemia (35.83%) and in chemotherapy (50.2%). Metastasis occurred in 16.41% and recurrence in 22.38%. There was no report of family history of cancer in 47% of the charts. Other pathologies were denied in 58.9%. In the end, 55.2% were alive and disease-free. There was a statistically significant association between boys younger than 10 years old with renal tumors and neuroblastoma and older than 10 years with lymphomas and malignant epithelial neoplasms and between the current status of the patient with metastasis, relapses, and staging. Conclusion: The patients analyzed in this study were mostly leukemic, males and aged 1-4 years. Global and disease-free survival were, respectively, 70.3% and 71.63%.